The stock of Intrexon Corp (NYSE:XON) is a huge mover today! About 559,129 shares traded hands. Intrexon Corp (NYSE:XON) has declined 9.47% since February 29, 2016 and is downtrending. It has underperformed by 21.68% the S&P500.
The move comes after 5 months positive chart setup for the $3.42 billion company. It was reported on Oct, 3 by Barchart.com. We have $48.40 PT which if reached, will make NYSE:XON worth $2.36B more.
Analysts await Intrexon Corp (NYSE:XON) to report earnings on November, 14. They expect $-0.23 EPS, up 32.35% or $0.11 from last year’s $-0.34 per share. After $-0.29 actual EPS reported by Intrexon Corp for the previous quarter, Wall Street now forecasts -20.69% EPS growth.
Intrexon Corp (NYSE:XON) Ratings Coverage
Out of 6 analysts covering Intrexon (NYSE:XON), 4 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 67% are positive. Intrexon has been the topic of 10 analyst reports since July 27, 2015 according to StockzIntelligence Inc. The firm has “Overweight” rating by JP Morgan given on Tuesday, August 11. On Monday, July 27 the stock rating was maintained by Wunderlich with “Buy”. As per Monday, October 19, the company rating was maintained by Wunderlich. The company was maintained on Monday, January 25 by Mizuho. Mizuho upgraded the shares of XON in a report on Wednesday, November 11 to “Neutral” rating. The stock has “Neutral” rating given by Bank of America on Wednesday, October 14. Stifel Nicolaus initiated the shares of XON in a report on Monday, September 21 with “Buy” rating. The company was maintained on Tuesday, August 11 by Wunderlich. The rating was downgraded by Mizuho to “Underperform” on Tuesday, August 11. As per Tuesday, May 3, the company rating was initiated by JMP Securities.
According to Zacks Investment Research, “Intrexon Corporation is a biotechnology company. It provides synthetic biology services. The Company designs and produces modular DNA control systems and applications for human therapeutics, protein production, industrial products, agricultural biotechnology, and animal sciences. Its technologies include the UltraVector gene design and fabrication platform; Cell Systems Informatics; LEAP-cell identification and selection, and mAbLogix-antibody discovery. Intrexon Corporation is based in Germantown, Maryland.”
Insitutional Activity: The institutional sentiment decreased to 1.12 in Q2 2016. Its down 0.22, from 1.34 in 2016Q1. The ratio worsened, as 37 funds sold all Intrexon Corp shares owned while 40 reduced positions. 18 funds bought stakes while 68 increased positions. They now own 98.85 million shares or 1.45% less from 100.31 million shares in 2016Q1.
Bluemountain Cap Management Llc has 30,862 shares for 0.02% of their US portfolio. Marshall Wace Llp last reported 32,510 shares in the company. Lmm Ltd Liability reported 3.07M shares or 3.38% of all its holdings. Pnc Fincl Services Gp Incorporated holds 0% of its portfolio in Intrexon Corp (NYSE:XON) for 23,550 shares. Kanaly reported 250 shares or 0% of all its holdings. Moreover, Private Advisor Grp Inc Ltd Company has 0.04% invested in Intrexon Corp (NYSE:XON) for 39,682 shares. The New York-based Tiaa Cref Inv Mgmt Ltd has invested 0% in Intrexon Corp (NYSE:XON). Columbus Circle owns 54,209 shares or 0.01% of their US portfolio. Belmont Global Advsrs reported 280,550 shares or 6.63% of all its holdings. Franklin Street Advsrs Nc has 10,000 shares for 0.05% of their US portfolio. Blackrock Institutional Na last reported 0.01% of its portfolio in the stock. Moreover, Fund Sa has 0.01% invested in Intrexon Corp (NYSE:XON) for 64,927 shares. Aqr Capital Mngmt Limited Liability owns 1.39 million shares or 0.06% of their US portfolio. Addison Cap Co holds 21,017 shares or 0.47% of its portfolio. The Michigan-based Plante Moran Financial Advsrs Limited Liability Company has invested 0.07% in Intrexon Corp (NYSE:XON).
Insider Transactions: Since May 13, 2016, the stock had 2 insider purchases, and 0 sales for $1.11 million net activity. KIRK RANDAL J had bought 41,830 shares worth $1.00M. Shares for $104,484 were bought by Nimrodi Nir.
Another recent and important Intrexon Corp (NYSE:XON) news was published by Streetinsider.com which published an article titled: “Form 4/A INTREXON CORP For: Jun 01 Filed by: Germano Geno J” on September 26, 2016.
XON Company Profile
Intrexon Corporation (Intrexon), incorporated on June 1, 2010, forms collaborations to create biologically based products and processes using synthetic biology. The Company’s domestic activities are in California, Florida, Maryland, and Virginia, and its primary international activities are in Belgium and Hungary. The Firm designs, manufactures and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components. The Company’s synthetic biology capabilities include the ability to control the amount, location and modification of biological molecules to control the function and output of living cells and optimize for desired results at an industrial scale. The Company’s technologies combine the principles of precision engineering, statistical modeling, automation and production at an industrial scale. The Company’s technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; Cell Systems Informatics; RheoSwitch inducible gene switch; AttSite Recombinases; Protein Engineering; Laser-Enabled Analysis and Processing, or LEAP, and ActoBiotics platform.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.